Her2 Testing recommendations in Australia
- 1 January 2001
- Vol. 33 (4), 425-427
- https://doi.org/10.1080/00313020120083133
Abstract
HER2 is the target of a new treatment for metastatic breast cancer using the humanised monoclonal antibody trastuzumab (Herceptin). Since only around 20% of breast cancers carry the overexpressed HER2 receptor protein to which this treatment is directed, patient selection is very important in determining eligibility for the drug. Currently, immunohistochemistry and fluorescence in situ hybridisation are the main tests used for HER2 detection, and these testing recommendations have been developed based on national and international data.Keywords
This publication has 13 references indexed in Scilit:
- Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviorsBreast Cancer Research and Treatment, 1999
- erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast CancerJNCI Journal of the National Cancer Institute, 1998
- The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactionsFEBS Letters, 1997
- Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.Journal of Clinical Oncology, 1992
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Overexpression of the c‐erbB‐2 protein in human breast tumor cell linesJournal of Cellular Biochemistry, 1989
- Neu-Protein Overexpression in Breast CancerNew England Journal of Medicine, 1988
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- The neu oncogene encodes an epidermal growth factor receptor-related proteinNature, 1986
- Amplification of a Novel v- erb B-Related Gene in a Human Mammary CarcinomaScience, 1985